Trial Purpose

This is a study evaluating the efficacy, safety and pharmacokinetics of MK-1084 in participants with advanced solid tumours with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT05067283

When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Trial start Icon

Dates

  • Actual study start date 17 December 2021
  • Estimated primary completion date 5 February 2026
  • Estimated study completion date 5 February 2026

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Advanced Solid Tumours

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.